MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results
I'm LongbridgeAI, I can summarize articles.
MIRA Pharmaceuticals, Inc. reported positive Phase 1 results for Ketamir-2, an oral NMDA receptor modulator, in a study involving 57 healthy volunteers. The trial showed no serious adverse events and mild side effects, with a higher incidence of adverse events in the placebo group. The company plans to submit for Phase 2a FDA evaluation for chemotherapy-induced peripheral neuropathy. Analysts rate MIRA stock as a Buy with an $8.00 price target. MIRA focuses on developing novel therapeutics for pain management, with a current market cap of $42.86M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments